Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.

Literature DB >> 3193516

Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.

G Hienert¹, J C Kirchheimer, H Pflüger, B R Binder.

Abstract

Plasma levels of urokinase-type plasminogen activator have been investigated in 80 patients with prostatic carcinoma by means of a radioimmunoassay. A total of 30 patients with disseminated prostatic carcinoma had significantly elevated levels of urokinase-type plasminogen activator, whereas the plasma levels in patients without metastases did not differ from a healthy age matched control group. Sensitivity of elevated urokinase-type plasminogen activator levels in patients with prostatic carcinoma for the presence of metastases was 80 per cent. Therefore, urokinase-type plasminogen activator appears to be a reliable marker for the formation of metastases in prostatic carcinoma.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1988 PMID： 3193516 DOI： 10.1016/s0022-5347(17)42074-x

Source DB: PubMed Journal: J Urol ISSN： 0022-5347 Impact factor: 7.450

Keyword Cloud
Cited

15 in total

Review 1. Tumor markers in prostate cancer I: blood-based markers.

Authors: Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal: Acta Oncol Date: 2011-06 Impact factor: 4.089

2. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

Authors: Shahrokh F Shariat; Eduardo I Canto; Michael W Kattan; Kevin M Slawin
Journal: Rev Urol Date: 2004

3. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

Authors: G A Soff; J Sanderowitz; S Gately; E Verrusio; I Weiss; S Brem; H C Kwaan
Journal: J Clin Invest Date: 1995-12 Impact factor: 14.808

4. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.

Authors: D M Ignar; J L Andrews; S M Witherspoon; J D Leray; W C Clay; K Kilpatrick; J Onori; T Kost; D L Emerson
Journal: Clin Exp Metastasis Date: 1998-01 Impact factor: 5.150

5. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Authors: D Samid; S Shack; C E Myers
Journal: J Clin Invest Date: 1993-05 Impact factor: 14.808

10. Long term increased expression of the short form 1b prolactin receptor in PC-3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity.

Authors: Kuang-tzu Huang; Ameae M Walker
Journal: Prostate Date: 2010-01-01 Impact factor: 4.104

Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.

Review 1. Tumor markers in prostate cancer I: blood-based markers.

2. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

3. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

4. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.

5. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

6. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance.

7. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

8. The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells.

Review 9. The plasminogen-plasmin system in malignancy.

10. Long term increased expression of the short form 1b prolactin receptor in PC-3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity.